Navigation Links
Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting

Diversity of Abstracts Reflects Continued Growth of Eisai's Commitment to Oncology

WOODCLIFF LAKE, N.J., May 31, 2007 /PRNewswire/ -- Eisai announced today that several abstracts covering clinical data about their oncology pipeline compounds have been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. ASCO takes place in Chicago from June 1-5, 2007.

These abstracts reveal a growing and diverse oncology clinical development program at Eisai. In addition to the variety of oncology product classes under investigation, these compounds are being studied in advanced diseases where there remains considerable unmet medical need, particularly in refractory metastatic breast cancer, advanced non-small cell lung cancer, and advanced ovarian cancer.

The following abstracts highlight data from pipeline compounds that have been accepted for presentation at this year's ASCO meeting.

    Product        Abstract Details                        Location Details

    Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00

    Mesylate       (E7389) Halichondrin B Analog in        AM - 1:00 PM

    (E7389)        Patients with Refractory Breast Cancer  Location: S403

    Abstract No:   Poster Number: 21


    Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00

    Mesylate       (E7389), a Mechanistically Novel        AM - 1:00 PM

    (E7389)        Inhibitor of Microtubule Dynamics,      Location: E451a

    Abstract No:   in Patients with Advanced Non-Small

    7546           Cell Lung Cancer (nsclc)

                   Poster Number: 20

    MORAb-003      Novel Phase II Study Design of          June 2, 2007

    Abstract No:   MORAb-003, a Monoclonal Antibody        2:00 PM - 6:00 PM

    5583           against Folate Receptor Alpha in        Location: S Hall A2

                   Platinum-Sensitive Ovarian Cancer

                   in First Relapse

               Poster Number: U4

    MORAb-003      A Phase I Study of MORAb-003, a Fully   June 2, 2007

    Abstract No:   Humanized Monoclonal Antibody against   2:00 PM - 6:00 PM

    5553           Folate Receptor Alpha, in Advanced      Location: S Hall A2

                   Epithelial Ovarian Cancer

                   Poster Number: R7

    E7974          A Phase I Trial of E7974 Administered   June 3, 2007

    Abstract No:   on Days 1 and 15 of a 28-Day Cycle in   8:00 AM - 12:00 PM

    2550           Patients With Solid Malignancies        Location: S Hall A2

                   Poster Number: B6

    E7974          A Phase I Trial of E7974 Administered   June 3, 2007

    Abstract No:   on Days 1, 8, and 15 of a 28-Day Cycle  8:00 AM - 12:00 PM

    2543           in Patients With Solid Malignancies     Location: S Hall A2

                   Poster Number: A13

The expansion of Eisai's oncology discovery, research and clinical development capabilities complements the company's establishment of its oncology sales and marketing operations in the United States. Through its acquisition in 2006 of four marketed oncology products, Eisai also obtained key oncology personnel and expertise, including a sales force. Most recently, Eisai acquired Morphotek, Inc., which discovers and develops therapeutic monoclonal antibodies through its proprietary technologies. Morphotek has preclinical and clinical development programs underway in several therapeutic categories, including oncology. Both acquisitions expand Eisai's capabilities into the biologic therapeutics field.

Eisai is committed to building its commercial oncology infrastructure and is well positioned to market new oncology products that originate from its research and discovery efforts or through future acquisition, co-promotion or in-licensing opportunities. That growth will help Eisai address the unmet medical needs of patient s, especially cancer patients, throughout the world.

About Eisai Inc.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ended March 31, 2007).

Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. For more information about Eisai, please visit

About Eisai Medical Research Inc.

Eisai Medical Research Inc., a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., headquartered in Ridgefield Park, NJ, is focused on clinical drug development of new chemical entities and of new indications for marketed products.

About Morphotek, Inc.

Morphotek(R), Inc., a U.S. subsidiary of Eisai Co., Ltd., was acquired by Eisai in April 2007. Founded in 2000 and located in Exton, PA, Morphotek is a biopharmaceutical company which discovers and develops monoclonal antibodies through the use of proprietary human antibody technology called Human MORPHODOMA(R). Morphotek has assembled a strong pipeline of lead products in the areas of oncology and inflammation and infectious diseases. It has programs in clinical development and in preclinical stage moving towards IND filing. For further information, visit

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 9,000 people worldwide.

CONTACT: Judee Shuler of Eisai, during ASCO: +1-908-337-2540, or office:+1-201-746-2241

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from reveals that behind the tendency to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):